Free Trial
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

Verona Pharma plc (VRP.L) logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
55
55
52-Week Range
N/A
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
Aggregate Rating
N/A

ETF Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

VRP ETF News Headlines

Do this Before Elon’s Reveal on April 23rd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
See More Headlines

VRP ETF - Frequently Asked Questions

Verona Pharma plc (VRP.L) (LON:VRP) issued its quarterly earnings data on Thursday, February, 27th. The company reported ($30.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($30.80) by $0.50.

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (LON:VRP) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners